As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
AURA Division specialises in Antiretroviral therapies and viral disease management. With a strong legacy of expertise in HIV care, tuberculosis, latent TB infection and other anti-infectives, this division provides a vast range of treatment solutions that aim at improving patient adherence and therapeutic outcomes.
Through Hetero Healthcare’s commitment to innovation, affordability and excellence, the AURA division continues to support doctors with trusted therapies that address evolving patient needs in infectious disease management.
View by-
